Literature DB >> 19921477

Osteopontin silencing by small interfering RNA induces apoptosis and suppresses invasion in human renal carcinoma Caki-1 cells.

Aimin Zhang1, Yi Liu, Yizheng Shen, Youhe Xu, Xiangtie Li.   

Abstract

Antiapoptosis and invasion are the causes for the failure of conventional radiotherapy and chemotherapy in human renal carcinomas. Osteopontin (OPN), a ligand for vß3 integrin and CD44 receptors, is a phosphorylated glycoprotein with diverse functions including tumorigenesis and tumor cell metastasis. Recently, OPN has been detected in human renal carcinomas and assessed as a potential prognostic marker of renal carcinomas. However, the function and mechanism of OPN in renal carcinomas remain unknown. In this study, we used OPN siRNA to silence the expression of OPN in renal carcinoma Caki-1 cells. Silent effect showed that sequence-specific siRNA targeting OPN suppressed OPN mRNA expression by 81% and OPN protein level by 91% in vitro. The apoptosis ability was significantly increased while the invasion ability was decreased in Caki-1 cells transfected with OPN siRNA. Western blot demonstrated that the effects of OPN silence were significantly accompanied by the activation of mitochondria-related apoptosis pathway involving cytochrome c, Apaf-1, cleaved caspase-3 and Bcl-2/Bax, and the downregulation of invasion-related proteins of MMP-2 and uPA expression. These results suggest that the downregulation of OPN expression can induce apoptosis increase and invasion suppression in renal carcinoma Caki-1 cells through mitochondria-related apoptosis pathway and MMP-2 and uPA-related invasion proteins, respectively.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19921477     DOI: 10.1007/s12032-009-9356-z

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  24 in total

1.  Alpha-V-dependent outside-in signaling is required for the regulation of CD44 surface expression, MMP-2 secretion, and cell migration by osteopontin in human melanoma cells.

Authors:  V Samanna; H Wei; D Ego-Osuala; M A Chellaiah
Journal:  Exp Cell Res       Date:  2006-04-24       Impact factor: 3.905

2.  Co-expression of osteopontin and CD44v9 in gastric cancer.

Authors:  T Ue; H Yokozaki; Y Kitadai; S Yamamoto; W Yasui; T Ishikawa; E Tahara
Journal:  Int J Cancer       Date:  1998-04-17       Impact factor: 7.396

Review 3.  Renal cell carcinoma: diagnosis, staging, and surveillance.

Authors:  Chaan S Ng; Christopher G Wood; Paul M Silverman; Nizar M Tannir; Pheroze Tamboli; Carl M Sandler
Journal:  AJR Am J Roentgenol       Date:  2008-10       Impact factor: 3.959

4.  Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked.

Authors:  J Yang; X Liu; K Bhalla; C N Kim; A M Ibrado; J Cai; T I Peng; D P Jones; X Wang
Journal:  Science       Date:  1997-02-21       Impact factor: 47.728

5.  Osteopontin expression correlates with prognostic variables and survival in clear cell renal cell carcinoma.

Authors:  Koviljka Matusan; Gordana Dordevic; Darko Stipic; Vladimir Mozetic; Ksenija Lucin
Journal:  J Surg Oncol       Date:  2006-09-15       Impact factor: 3.454

6.  Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma.

Authors:  N Shijubo; T Uede; S Kon; M Maeda; T Segawa; A Imada; M Hirasawa; S Abe
Journal:  Am J Respir Crit Care Med       Date:  1999-10       Impact factor: 21.405

7.  Inhibition of apoptosis as a mechanism of tumor promotion.

Authors:  S C Wright; J Zhong; J W Larrick
Journal:  FASEB J       Date:  1994-06       Impact factor: 5.191

8.  Osteopontin: possible role in prostate cancer progression.

Authors:  G N Thalmann; R A Sikes; R E Devoll; J A Kiefer; R Markwalder; I Klima; C M Farach-Carson; U E Studer; L W Chung
Journal:  Clin Cancer Res       Date:  1999-08       Impact factor: 12.531

9.  Osteopontin expression in a group of lymph node negative breast cancer patients.

Authors:  A B Tuck; F P O'Malley; H Singhal; J F Harris; K S Tonkin; N Kerkvliet; Z Saad; G S Doig; A F Chambers
Journal:  Int J Cancer       Date:  1998-10-23       Impact factor: 7.396

10.  Human macrophages promote the motility and invasiveness of osteopontin-knockdown tumor cells.

Authors:  Jiasen Cheng; De-Hua Huo; Dong-Ming Kuang; Jine Yang; Limin Zheng; Shi-Mei Zhuang
Journal:  Cancer Res       Date:  2007-06-01       Impact factor: 12.701

View more
  10 in total

1.  Osteopontin reduced hypoxia-ischemia neonatal brain injury by suppression of apoptosis in a rat pup model.

Authors:  Wanqiu Chen; Qingyi Ma; Hidenori Suzuki; Richard Hartman; Jiping Tang; John H Zhang
Journal:  Stroke       Date:  2011-01-27       Impact factor: 7.914

2.  Studies on the role of osteopontin-1 in endometrial cancer cell lines.

Authors:  J C Hahne; S R Meyer; P Kranke; J Dietl; M Guckenberger; B Polat; A Hönig
Journal:  Strahlenther Onkol       Date:  2013-10-16       Impact factor: 3.621

3.  The potential of osteopontin as a therapeutic target for human colorectal cancer.

Authors:  Wang Likui; Wang Hong; Zhang Shuwen; You Yuangang; Wen Yan
Journal:  J Gastrointest Surg       Date:  2011-02-12       Impact factor: 3.452

Review 4.  Bone sialoprotein and osteopontin in bone metastasis of osteotropic cancers.

Authors:  Thomas E Kruger; Andrew H Miller; Andrew K Godwin; Jinxi Wang
Journal:  Crit Rev Oncol Hematol       Date:  2013-09-07       Impact factor: 6.312

5.  Curcumol induces apoptosis via caspases-independent mitochondrial pathway in human lung adenocarcinoma ASTC-a-1 cells.

Authors:  Weiwei Zhang; Zhiping Wang; Tongsheng Chen
Journal:  Med Oncol       Date:  2010-02-03       Impact factor: 3.064

6.  Osteopontin is an endogenous modulator of the constitutively activated phenotype of pulmonary adventitial fibroblasts in hypoxic pulmonary hypertension.

Authors:  Adil Anwar; Min Li; Maria G Frid; Binod Kumar; Evgenia V Gerasimovskaya; Suzette R Riddle; B Alexandre McKeon; Roopa Thukaram; Barbara O Meyrick; Mehdi A Fini; Kurt R Stenmark
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-05-11       Impact factor: 5.464

7.  Osteopontin expression in the brain triggers localized inflammation and cell death when immune cells are activated by pertussis toxin.

Authors:  Maria Cecilia Garibaldi Marcondes; Ryan Ojakian; Nikki Bortell; Claudia Flynn; Bruno Conti; Howard S Fox
Journal:  Mediators Inflamm       Date:  2014-11-24       Impact factor: 4.711

8.  Suppression of osteopontin inhibits chemically induced hepatic carcinogenesis by induction of apoptosis in mice.

Authors:  Su-Hyung Lee; Jun-Won Park; Sang-Ho Woo; Du-Min Go; Hyo-Jung Kwon; Ja-June Jang; Dae-Yong Kim
Journal:  Oncotarget       Date:  2016-12-27

9.  The interaction of YBX1 with G3BP1 promotes renal cell carcinoma cell metastasis via YBX1/G3BP1-SPP1- NF-κB signaling axis.

Authors:  Yong Wang; Jing Su; Yiting Wang; Donghe Fu; Justin E Ideozu; Hua Geng; Qiqi Cui; Chao Wang; Ruibing Chen; Yixi Yu; Yuanjie Niu; Dan Yue
Journal:  J Exp Clin Cancer Res       Date:  2019-09-03

10.  Anti-apoptotic effects of osteopontin through the up-regulation of Mcl-1 in gastrointestinal stromal tumors.

Authors:  Kai-Hsi Hsu; Hung-Wen Tsai; Pin-Wen Lin; Yun-Shang Hsu; Pei-Jung Lu; Yan-Shen Shan
Journal:  World J Surg Oncol       Date:  2014-06-20       Impact factor: 2.754

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.